Lung Cancer
Volume 69, Issue 3 , Pages 265-271, September 2010

Rationale of a relaunch of gefitinib in Caucasian non-small cell lung cancer patients

  • Andreas Pircher

      Affiliations

    • Medical University Innsbruck, Department of Internal Medicine V, Hematology and Oncology, Anichstrasse 35, 6020 Innsbruck, Austria
    • Corresponding Author InformationCorresponding authors. Tel.: +43 512 504 82430; fax: +43 512 504 26299.
    • ,
  • Ferdinand Ploner

      Affiliations

    • Medical University Graz, Department of Oncology, Auenbruggerplatz 15, 8036 Graz, Austria
    • ,
  • Helmut Popper

      Affiliations

    • Medical University Graz, Institute of Pathology, Auenbruggerplatz 15, 8036 Graz, Austria
    • ,
  • Wolfgang Hilbe

      Affiliations

    • Medical University Innsbruck, Department of Internal Medicine V, Hematology and Oncology, Anichstrasse 35, 6020 Innsbruck, Austria
    • Corresponding Author InformationCorresponding authors. Tel.: +43 512 504 82430; fax: +43 512 504 26299.

Received 30 September 2009; received in revised form 18 January 2010; accepted 24 January 2010. published online 19 February 2010.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0169-5002(10)00060-7

doi:10.1016/j.lungcan.2010.01.017

Lung Cancer
Volume 69, Issue 3 , Pages 265-271, September 2010

Article Tools

* Image Usage & Resolution